CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Open-market sale Director sold 38,353 shares at an average $59.72 ($2,290,536)
- 4 Option exercise Chief Scientific Officer acquired 9,996 shares (option exercise)
- 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $64.56 ($64,556)
- 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $64.48 ($341,750)
- 4 Open-market sale Director sold 23,959 shares at an average $56.45 ($1,352,499)
- 4 Open-market sale Director sold 23,690 shares at an average $61.13 ($1,448,078)
- 4 Option exercise Chief Scientific Officer acquired 33,200 shares (option exercise)
- 4 Open-market sale Director sold 28,617 shares at an average $60.87 ($1,742,043)
- 4 Open-market sale Director sold 19,029 shares at an average $63.53 ($1,208,936)
- 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $64.84 ($64,841)
- 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $64.91 ($344,017)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 60,000 shares at $50.00 ($3,000,000)
- 4 Open-market buy Director bought 60,000 shares at $50.00 ($3,000,000)
- 4 Open-market buy 10% owner bought 60,000 shares at $50.00 ($3,000,000)
Page 9 of 11 · 207 filings